

Low-dose doxycycline in the treatment of periodontitis in smokers

Submission date 15/10/2002	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 15/10/2002	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 24/11/2010	Condition category Other	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Ian Needleman

Contact details
Department of Periodontology
Eastman Dental Institute for Oral Health Care Sciences
University College London
256 Gray's Inn Road
London
United Kingdom
WC1X 8LD
+44 (0) 20 7915 2340
i.needleman@eastman.ucl.ac.uk

Additional identifiers

Study information

Scientific Title

Study objectives
Not provided at time of registration.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration.

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Periodontology

Interventions

1. Non-surgical periodontal therapy plus twice daily 20 mg doxycycline for 3 months
2. Non-surgical periodontal therapy plus twice daily placebo for 3 months

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Not provided at time of registration.

Key secondary outcome(s)

Not provided at time of registration.

Completion date

15/10/2005

Eligibility**Key inclusion criteria**

1. Smokers unable to quit
2. Moderate-severe chronic periodontitis
3. Age 30-70

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration.

Date of first enrolment

15/10/2000

Date of final enrolment

15/10/2005

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Department of Periodontology

London

United Kingdom

WC1X 8LD

Sponsor information**Organisation**

CollaGenex Pharmaceuticals Inc. (USA)

ROR

<https://ror.org/01rdxvn05>

Funder(s)**Funder type**

Industry

Funder Name

Mainly self-supported: design, conduct, analysis and reporting are independent of industry.
Biochemical analyses funded by CollaGenex Inc.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2007		Yes	No